- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.07. | Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial | ||
| 24.07. | Amgen hands in data package in hopes of FDA hearing for Tavneos defense | ||
| 24.07. | Merck stages expanded access to monthly HIV PrEP pill ahead of approval | ||
| 24.07. | GSK's first lung cancer approval, a new IPO path and more | ||
| 23.07. | In FDA compounding adcomm, advisers urge against restrictions on 1st of 7 peptides | ||
| 23.07. | Roche defends 6B franc Vabysmo peak sales target despite another quarterly miss | ||
| 23.07. | BeOne jumps aboard onshoring train with $300M to add small molecule production in US | ||
| 23.07. | FDA rebukes 2 Indian API plants over data controls, sanitation issues | ||
| 22.07. | GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal | ||
| 22.07. | FDA calls out Sanofi emails for giving 'misleading impression' of Beyfortus use in RSV | ||
| 22.07. | What to Expect at PODD 2026 | ||
| 22.07. | Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data | ||
| 22.07. | Trump floats countdown to 200% tariffs on generic drugs imported to US | ||
| 22.07. | Summit Therapeutics updates ivonescimab survival data ahead of FDA decision date | ||
| 22.07. | Sanofi reprimanded for disparaging Pfizer's RSV vaccine | ||
| 21.07. | Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill | ||
| 21.07. | Sanofi continues tweaks to executive roster as new CEO Garijo settles in | ||
| 21.07. | Alembic site slapped with FDA warning letter over patient consent concerns | ||
| 21.07. | Lilly, BMS aerospace partner Redwire opens new site in Indiana | ||
| 21.07. | Novartis CEO brushes off oral PCSK9 competition as Leqvio drives Q2 growth | ||
| 21.07. | Gilead, Merck's phase 3 data back first weekly HIV pill | ||
| 21.07. | Novo Nordisk files lawsuit accusing rival Eli Lilly of running 'false and misleading' GLP-1 ads | ||
| 21.07. | J&J's Tremfya remains on top in Q2 pharma ad spending league as overall outlay drops | ||
| 21.07. | The Oral GLP-1 Tracker: Lilly's Foundayo scripts tick up amid overall obesity market slowdown | ||
| 20.07. | Sanofi survey uncovers Type 1 diabetes misconceptions and screening gaps |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.